Supplementary Materials

Supplementary Material for:

Targeting phosphatase-dependent proteoglycan switch for rheumatoid arthritis therapy

Karen M. Doody, Stephanie M. Stanford, Cristiano Sacchetti, Mattias N. D. Svensson, Charlotte H. Coles, Nikolaos Mitakidis, William B. Kiosses, Beatrix Bartok, Camille Fos, Esther Cory, Robert L. Sah, Ru Liu-Bryan, David L. Boyle, Heather A. Arnett, Tomas Mustelin, Maripat Corr, Jeffrey D. Esko, Michel L. Tremblay, Gary S. Firestein, A. Radu Aricescu, Nunzio Bottini*

*Corresponding author. E-mail: nunzio{at}lji.org

Published 20 May 2015, Sci. Transl. Med. 7, 288ra76 (2015)
DOI: 10.1126/scitranslmed.aaa4616

This PDF file includes:

  • Materials and Methods
  • Fig. S1. Expression of PTPRS in OA and RA FLS.
  • Fig. S2. Reduction of surface HS inhibits migration of FLS in an RPTPσ-dependent manner.
  • Fig. S3. Knockdown of PTPRS in RA FLS.
  • Fig. S4. RPTPσ Ig1&2 does not affect FLS survival.
  • Fig. S5. RPTPσ Ig1&2 treatment does not affect FLS response to cytokine stimulation.
  • Fig. S6. RPTPσ Ig1&2 decreases cell attachment to fibronectin.
  • Fig. S7. Knockdown of SDC2/GPC1 and SDC4 in RA FLS.
  • Fig. S8. Reconstitution of Ptprs KO FLS with RPTPσ mutants.
  • Fig. S9. RPTPσ Ig1&2 does not affect paxillin, FAK, or p130Cas phosphorylation in FLS.
  • Fig. S10. RPTPσ Ig1&2 decreases colocalization of ezrin with the actin cytoskeleton during migration.
  • Fig. S11. RPTPσ Ig1&2 does not alter β-catenin or cadherin-11 phosphorylation and does not affect cadherin-11 functions in FLS.
  • Fig. S12. RPTPσ Ig1&2 does not affect PDGFR expression or downstream Akt/MAPK signaling in FLS.
  • Fig. S13. Ptprs deficiency does not affect severity of K/BxN acute serum transfer arthritis.
  • Fig. S14. Expression of R2A subclass of PTPs in FLS.
  • Fig. S15. RPTPσ Ig1&2 does not affect macrophage response to stimulation.
  • Fig. S16. Blockade of peripheral nervous system arms does not affect arthritis in the K/BxN model.
  • Fig. S17. RPTPσ Ig1&2 does not affect K/BxN serum–induced vascular permeabilization of peripheral joints.
  • References (3644)

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S1 (Microsoft Excel format). Source data for Fig. 1 (A, B, and D).
  • Table S2 (Microsoft Excel format). Source data for fig. S1.
  • Table S3 (Microsoft Excel format). Source data for fig. S4.
  • Table S4 (Microsoft Excel format). Source data for fig. S5.
  • Table S5 (Microsoft Excel format). Source data for Fig. 2H.
  • Table S6 (Microsoft Excel format). Source data for fig. S6.
  • Table S7 (Microsoft Excel format). Source data for Fig. 3 (B and C).
  • Table S8 (Microsoft Excel format). Source data for Fig. 4A.
  • Table S9 (Microsoft Excel format). Source data for fig. S7 (A and B).
  • Table S10 (Microsoft Excel format). Source data for Fig. 5B.
  • Table S11 (Microsoft Excel format). Source data for Fig. 6 (A to H).
  • Table S12 (Microsoft Excel format). Source data for fig. S13A.
  • Table S13 (Microsoft Excel format). Source data for fig. S14.
  • Table S14 (Microsoft Excel format). Source data for fig. S15.
  • Table S15 (Microsoft Excel format). Source data for fig. S16 (A to C).
  • Table S16 (Microsoft Excel format). Source data for fig. S17.
  • Source Data 1 (.pdf format). Full Western blots (Fig. 1E).
  • Source Data 2 (.pdf format). Full Western blots (Fig. 4, E and F).
  • Source Data 3 (.pdf format). Full Western blots (Fig. 5, B to D).
  • Source Data 4 (.pdf format). Flow cytometry data (fig. S2A).
  • Source Data 5 (.pdf format). Flow cytometry gating (fig. S4).
  • Source Data 6 (.pdf format). Flow cytometry gating (fig. S8).
  • Source Data 7 (.pdf format). Full Western blots (fig. S9).
  • Source Data 8 (.pdf format). Full Western blots (fig. S11).
  • Source Data 9 (.pdf format). Full Western blots (fig. S12).

[Download Data Files S1 to S9]

[Download Tables S1 to S16]